| Document Date: 2015-01-28 11:41:43
Open Document File Size: 342,06 KBShare Result on Facebook
City Bonn / / Company CHMP 1 N.A. / N.A. 22 N.A. / N/A 6275 2590 2642 82 N.A. / N.A. 5 N.A. / N.A. 3 N.A. / N.A. 39 N.A. / N.A. 2 N.A. / N/A 4044 1944 1509 10 N.A. / N/A 5640 2298 2167 69 N.A. / / / Event Product Recall / Product Issues / / / IndustryTerm active substance applications / extension applications / herbal traditional use applications / category products / apomorphine-containing products / authorised products / chemical substances / generic drug applications / human products / medicinal products / / Organization Working Party on Paediatric Regulation / CMDh Secretariat / European Union / EMA Management Board / CMDh/European Medicines Agency Working Party / / Person Peter Bachmann / / / Position chair / / Product ceftazidime / CMDh / / ProgrammingLanguage EC / / PublishedMedium the Best Practice Guide / the CMDh Best Practice Guide / / URL http /
SocialTag |
Report from the CMDh meeting held onJanuary 2015 Pharmacovigilance Outcomes of informal PSUR work-sharing procedures The CMDh has adopted the conclusions of PSUR assessments for ceftazidime, influenza vaccine (spl